Treating cancer with a longevity-promoting drug: Acarbose, the widely used drug in the treatment of NIDDM, suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target genes, 6/October/2014, 5.27 am

Natural product-based therapy for Human cancer: (6)-gingerol (6G), the pungent component of Ginger, inhibits tumor cell proliferation via down regulation of Superoxide dismutase 1 (SOD1), 6/October/2014, 5.06 am
October 5, 2014
MiRNA-based Regenerative therapy for DM: MiRNA-182 promotes reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up regulation of Ngn3, 6/September/2014, 5.55 am
October 6, 2014
Show all

The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the University of Colorado BioFrontiers Institute, USA has published a research paper in the 13 December 2012 Nature (492(7428):285-9; I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.”  This study provides mechanistic insights into how TPP1 regulates telomerase function.

In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that:  Treating cancer with a longevity-promoting drug: Acarbose, the widely used drug in the treatment of NIDDM, suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target genes.  Remarkably, over 90% human tumors over express telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy.  A recent study suggests that acarbose promotes longevity in mice, highlighting an added advantage of this drug being an anti-cancer agent. Together, this study suggests that pharmacological formulations encompassing Acarbose or its analogues may be used to treat human cancers. 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan,   Treating cancer with a longevity-promoting drug: Acarbose, the widely used drug in the treatment of NIDDM, suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target genes, 6/October/2014, 5.27 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.